{"id":27000,"date":"2026-02-27T23:06:46","date_gmt":"2026-02-27T23:06:46","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/27000\/"},"modified":"2026-02-27T23:06:46","modified_gmt":"2026-02-27T23:06:46","slug":"abbott-signs-pact-with-novo-nordisk-to-offer-semaglutide","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/27000\/","title":{"rendered":"Abbott signs pact with Novo Nordisk to offer semaglutide"},"content":{"rendered":"<p>Mumbai: Abbott has entered into a strategic collaboration with <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/novo-nordisk\" target=\"_blank\" rel=\"nofollow noopener\">Novo Nordisk<\/a> India to commercialise another brand of Novo\u2019s blockbuster GLP-1 drug <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/ozempic\" target=\"_blank\" rel=\"nofollow noopener\">Ozempic<\/a> (semaglutide). The partnership, which comes less than a month ahead of <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/semaglutide\" target=\"_blank\" rel=\"nofollow noopener\">semaglutide<\/a>\u2019s patent expiry in India, is a key move by the Danish drug innovator to expand access in India beyond the regions it currently serves by leveraging Abbott\u2019s distribution network.<\/p>\n<p>Abbott\u2019s drug will be marketed under the brand name Extensior and is indicated for people living with type 2 diabetes.<br \/>Semaglutide, sold by Novo Nordisk under brands such as Ozempic and <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/wegovy\" target=\"_blank\" rel=\"nofollow noopener\">Wegovy<\/a>, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.<\/p>\n<p>Extensior will be introduced in India as part of Abbott\u2019s expanding portfolio of advanced diabetes solutions and is expected to be available for Indian patients soon, Abbott said in a statement.<\/p>\n<p>\u201cIndia is facing one of the world\u2019s fastest-growing diabetes burdens, and addressing this challenge requires continuous innovation and strong partnerships,\u201d said Kartik Rajendran, managing director, <a rel=\"dofollow noopener\" href=\"https:\/\/m.economictimes.com\/abbott-india-ltd\/stocks\/companyid-13937.cms\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" target=\"_blank\">Abbott India<\/a>. <\/p>\n<p><img decoding=\"async\" alt=\"ET logo\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/118783427.cms.png\" width=\"90%\"\/>Live Events<br \/>\u201cThe launch of Extensior builds on Abbott\u2019s long-standing focus on holistic diabetes management\u2014from medicines to diagnostics, and from continuous glucose monitoring to diabetes-specific nutrition,\u201d he added.<br \/>\u201cOur partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India,\u201d said Vikrant Shrotriya, managing director, Novo Nordisk India.More than 100 million individuals in India live with diabetes and this is projected to surge 50% to more than 150 million by 2050 driven by rapid urbanisation, aging populations, increasing obesity and lifestyle changes.<\/p>\n<p>Cardiovascular and kidney issues now account for much of the long-term risk faced by people living with type 2 diabetes. In India, about 43% of individuals with diabetes remain undiagnosed, limiting opportunities for early intervention.<\/p>\n<p>Extensior will be available in the FlexTouch Pen\u2014a once-weekly pen device that provides precise dosing in 0.25 mg, 0.5 mg and 1 mg dose strengths.<\/p>\n","protected":false},"excerpt":{"rendered":"Mumbai: Abbott has entered into a strategic collaboration with Novo Nordisk India to commercialise another brand of Novo\u2019s&hellip;\n","protected":false},"author":2,"featured_media":27001,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[17034,17404,272,3102,689,1910,277],"class_list":{"0":"post-27000","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-abbott-india","9":"tag-fat-loss-drugs","10":"tag-novo-nordisk","11":"tag-ozempic","12":"tag-semaglutide","13":"tag-wegovy","14":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/27000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=27000"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/27000\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/27001"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=27000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=27000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=27000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}